FTC Says Anesthesia Group Cheered While Raising Prices

By Matthew Perlman · March 30, 2026, 4:45 PM EDT

The Federal Trade Commission pushed back against a bid from U.S. Anesthesia Partners to avoid facing trial on claims that it monopolized the market through a rollup strategy, saying the company...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Response

Case Information

Case Title

Federal Trade Commission v. U.S. Anesthesia Partners, Inc. et al

Case Number

Court

Texas Southern

Nature of Suit

Anti-Trust

Date Filed

September 21, 2023

Recent Articles By Matthew

March 24, 2026
FTC To Mull Caremark Deal In PBM Insulin Pricing Case
March 23, 2026
FTC Stays Focused On Healthcare, Launches Task Force
March 17, 2026
Alcon Drops $430M Lensar Deal Under Pressure From FTC
March 11, 2026
Insulin Makers Ask Justices To Review Collusion Case
February 24, 2026
8th Circ. Won't Revive Iowa Pathology Lab's Antitrust Claims
February 20, 2026
DOJ Says Ohio Health System's Contracts Violate Antitrust
February 18, 2026
Sandoz's Case Against Amgen Over Enbrel Biosimilar Tossed
February 12, 2026
FTC's PBM Case Paused For More Deal Talks
February 11, 2026
Anesthesia Group Looks To End FTC Rollup Suit
January 30, 2026
FTC Requires Facility Sales For $835M Healthcare Deal